Asset Grazing

Cherry picking

While Corixa Corp. last week acquired all the assets of Anergen Inc., Cantab Pharmaceuticals plc chose to cherry-pick from ImmuLogic Pharmaceutical Corp., obtaining rights to IMUL's last two unpartnered programs in a deal that was to be announced on Monday.

Jurek Sikorski, CEO of CTB, presaged his plans in September when he told BioCentury, "We've concluded we don't have enough products in development. We now have five in development and you need 10 to 12 products in the pipeline from preclinical on to have enough products to develop and partner. You can't get them all internally, so we're looking to acquire and license."